A Study of DS-9606a in Patients With Advanced Solid Tumors
Terminated · Phase 1 · NCT05394675
Conditions: Advanced Cancer, Metastatic Cancer, Germ Cell Tumor
At a glance
- Research payments reported, 2025
- $145,788
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 88
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- DS-9606a (drug)
- Dates
- Started 2022-05-31; completion 2026-02-06
- Results posted
- Not yet
This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-03-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $145,788 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mohammed N. Al Hallak, M.D. Hematology & Oncology · Detroit, MI
- Sarina A. Piha-paul, M.D. Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $135,788
- Karmanos Cancer Center, MI $10,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.